alpha Talks is a podcast dedicated to the topic of value creation and growth in Private Equity. Our host, Enno Krey, speaks to experienced buyout CEOs, operating partners, deal makers and advisors about their experience and lessons-learned in the industry.
Buy & Build: A Post-Merger Integration Success Story with Stijn Vos & Joost Heeremans
In this episode, Humatica Managing Partner Andros Payne speaks to Stijn Vos, CEO of the Esdec Solar Group and Joost Heeremans an Operating Partner with Rivean Capital (previously known as Gilde Buy out Partners) about the organizational secrets of buy & build success – how to grow top-line by 10x in just 4 years by acquiring and successfully integrating former competitors.
Coventya: Navigating 20 Years of Private Equity Value Growth with Dr. Thomas Costa
In this episode, Enno Krey speaks to Dr. Thomas Costa, former CEO of Coventya, a leading international specialty chemicals company. Thomas is a highly experienced Private Equity CEO who has led Coventya through 20 years of PE ownership while consistently delivering strong value growth to it's shareholders. Listen to learn more about his journey.
High Value Divestiture: How to Transform Organizations and Sell Non-Core Assets at Pace with Jouni Heinonen
In this episode, Enno Krey speaks to Jouni Heinonen, Managing Partner of HVD Partners, a service provider that helps companies efficiently divest non-core assets. Jouni is an experienced public and private company CEO and board member with over 25 years of executive-level experience working in Europe, Asia and the Americas.
The New Face of Value Creation: How Organizational Effectiveness Drives Enterprise Value with Andros Payne
In this episode, Enno Krey speaks to Andros Payne, Founder and Managing Partner of Humatica, a specialist advisor in organizational effectiveness for Private Equity. Andros has 30 years of industry experience and gives insights on what organizational effectiveness (OE) is and how funds and their portfolio companies can use it go grow value at pace and with minimal risk.